MetrumRG is pleased to welcome Dr. Eric Sobie and Dr. Katharina Wilkins to our Translational and Systems Pharmacology (TSP) group. Eric is joining as a Group Leader, Principal Scientist II, and Katharina as a Principal Scientist I.
“MetrumRG, and the Translational and Systems Pharmacology group in particular, are excited for Drs. Sobie and Wilkins to join the TSP leadership team,” said Eric Jordie, Vice President and leader of the TSP group. “Their considerable passion, technical expertise, publication history, and mentoring experience will be instrumental to the continued evolution and growth of the TSP group, refinement of the group’s vision, thought leadership, and examples of M&S implementations to the scientific community. Their significant history of excellence in the field and expansive experience will also immediately increase the group’s capacity and capabilities to collaborate with clients on future projects.”
Eric Sobie’s research is internationally recognized and continues to influence the fields of pharmacometrics and systems pharmacology. He has served as Principal Investigator for an extensive and diverse portfolio of research projects, with grant funding from institutes such as the National Institutes of Health, the American Heart Association, and the National Science Foundation. Publications from his group have provided important new insight into treatments for heart disease, mechanisms of arrhythmia, and drug-induced adverse events. Eric is currently Professor of Pharmacological Sciences at the Icahn School of Medicine at Mount Sinai. He has also served in administrative leadership roles there, including Director of the Integrated Training Program in Pharmacological Sciences and Senior Associate Dean in the Graduate School of Biomedical Sciences. Eric’s distinguished research and leadership have been recognized by his colleagues and mentees at the school with the Lamport Research Award and the “Best Mentor” award.
“MetrumRG and the TSP group are excited for Eric to join the team,” Jordie said. “We look forward to helping foster Eric’s passion for scientific research and his mentorship to further the reach of systems pharmacology toward our mission-driven goals of improving health and defeating disease, particularly where there are unmet needs.”
Katharina Wilkins joins MetrumRG with an impressive background as both a scientist and computational software engineer with research experience in biotechnology and biomedical engineering. Her journey began in Germany at the Karlsruhe Institute of Technology, continued on to the Ecole Superieure de Biotechnologie de Strasbourg in Strasbourg, France, and later came to the U.S., where she was a research fellow at New England Biolabs in Beverly, MA. Katharina received her Ph.D from the Department of Chemical Engineering at the Massachusetts Institute of Technology. After graduating, she solved electrophysiology cardiac mapping problems, using techniques from finite-element methods, computational physics, and inverse problems. Her design of an in silico trial simulation environment helped direct R&D efforts at Rhythmia Medical (now Boston Scientific) for the efficient planning of human and animal studies. Most recently, she applied mechanistic Quantitative Systems Pharmacology (QSP) modeling to support the development of immuno-oncology targets and therapeutics.
“Katharina’s expertise, complemented with her extensive programming and software skills, will immediately amplify TSP capabilities at MetrumRG,” Jordie said.
The team at MetrumRG is proud to end the year having significantly contributed to the development of oncology, immuno-oncology, gene therapy, and infectious disease assets with their collaborative scientific partners. The focus in 2023 is to build upon the excellence already provided by our longstanding TSP team members, while growing capacity, mentoring, and scientific thought leadership with the additions of Drs. Sobie and Wilkins.
Don’t forget to subscribe to the MetrumRG newsletter to receive the latest news about the team and their work!